ABBV vs ADMA · P/E 81, rev $61.16B vs P/E 22, rev $426.5M
AbbVie Inc (ABBV) versus ADMA Biologics Inc (ADMA) — a side-by-side from cached financials, not a winner call.
AbbVie Inc (ABBV) is a drug manufacturers - general company listed on US. It is led by Rob Michael.
ADMA Biologics Inc (ADMA) is a biotechnology company listed on US.
Latest reported ABBV revenue for 2025-12-31 was $61.16B. Net income was $4.23B. Revenue was up 305.0% from 2024-12-31 to 2025-12-31. ABBV currently screens at market cap $334.34B and trailing P/E 80.5.
Latest reported ADMA revenue for 2024-12-31 was $426.5M. Net income was $197.7M. Revenue was up 65.2% from 2023-12-31 to 2024-12-31. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
ABBV currently screens at market cap $334.34B and trailing P/E 80.5. ADMA currently screens at market cap $4.39B and trailing P/E 21.9.
Not investment advice. Open the ABBV and ADMA stock pages for the full models.
Not investment advice.